Pharma Benefits
Why pharma partners work with us.
Benefits
What better crystals unlock downstream.
Ultra-high concentration
Larger crystal volume per unit mass allows formulations several times more concentrated than conventional processes, without added excipients.
Formulation stability
More ordered crystal structures degrade more slowly, extending shelf life and easing cold-chain requirements for distribution.
Controlled release
Crystal size and geometry can be tuned to shape dissolution rate, enabling less frequent dosing for chronic conditions.
Why microgravity
Bigger, cleaner crystals than gravity allows.
01 — On Earth
Scattered, irregular
02 — In microgravity
Ordered, uniform
03 — The result
Assembled formulation
75–100µm
average crystal size
500µm+
average crystal size
3–5x
higher concentration
OnEarth,convectionandsedimentationdisturbcrystalsastheyform.Turbulencelimitshowlargeanduniformeachlatticecangrow,leavingsmaller,irregularstructuresscatteredthroughoutthesample.
Inmicrogravity,thatturbulencedisappears.Moleculesdriftintoplaceslowlyandassembleintocleaner,moreorderedlattices—farlargerandmoreuniformthananythinggrownundergravity.
Theresultisadenser,moreuniformcrystalstructure.Higherdrugloadingperdose,morepredictablerelease,andformulationsreadyforhigher-concentrationtherapies.
Who this is for
Biologics developers
De-risk formulation work on high-concentration monoclonal antibodies and other large-molecule therapeutics.
Commercial & supply teams
Reduce cold-chain dependency and simplify distribution with more stable, room-temperature-tolerant formulations.
Patients & providers
Move chronic-condition management out of the infusion suite and into the home, with fewer visits per year.
Haveamoleculethatbelongsinorbit?
Tell us about your biologic and we’ll assess it for microgravity crystallisation within two weeks.